

Title	FOA number(s)	FOA sponsor (e.g. NICHD, FDA)	Application Deadline	Brief Description
<u>Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54 Clinical Trials Optional)</u>	RFA-TR-18-020	Rare Diseases Clinical Research Consortia	9-Oct-2018	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite new and re-competing applications to apply to the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance the diagnosis, management, and treatment of rare diseases with a focus on clinical trial readiness.</p>
<u>Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)</u>	RFA-TR-18-021	National Institutes of Health	9-Oct-2018	<p>This Funding Opportunity Announcement (FOA) is to invite applications for new applications for the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Network (RDCRN). Each consortium within the RDCRN is intended to advance the diagnosis, management, and treatment of rare diseases.</p>

<p><u>Natural History Studies for Rare Disease Product Development: Orphan Products Research Project Grant (R01)</u></p>	<p>RFA-FD-16-043</p>	<p>Food and Drug Administration</p>	<p>15-Oct-2018</p>	<p>The objective of FDA's Orphan Products Natural History Grants Program is to support studies that advance rare disease medical product development through characterization of the natural history of rare diseases/conditions, identification of genotypic and phenotypic subpopulations, and development and/or validation of clinical outcome measures, biomarkers and/or companion diagnostics.</p>
<p><u>Natural History of Disorders Identifiable by Screening of Newborns (R01 Clinical Trial Optional)</u></p>	<p>PAR-18-090</p>	<p>Health and Human Services- National Institutes of Health 11</p>	<p>7-May-2019</p>	<p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening.</p>

<u>Natural History of Disorders Identifiable by Screening of Newborns (R01)</u>	PAR-16-061	Health and Human Services- National Institutes of Health 11	8-May-2019	This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening
<u>Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens (R03)</u>	PA-17-299	National Institute of Child Health and Human Development	7-May-2020	This Funding Opportunity Announcement (FOA) encourages applications that propose to conduct secondary analyses of publicly available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost-effective research utilizing data and biospecimens collected with NICHD resources.

<u>Ethical, Legal and Social Implications (ELSI) of Genomics Small Research Grant Program (R03)</u>	PA-17-445	NHGRI, NCI, NIA, NIAID, NICHD, NIDCD, NIDA, NIEHS	7-Sep-2020	This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research
<u>Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)</u>	PA-17-446	NHGRI, NCI, NIA, NIAID, NICHD, NIDCD, NIDA, NIEHS	7-Sep-2020	This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.
<u>Short-Term Research Education Program to Increase Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)</u>	RFA-HL-19-024	National Institutes of Health	6-May-2021	To support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in the mission areas of importance to NHLBI

<u>Innovative Therapies and Tools for Screenable Disorders (R01 Clinical Trial Optional)</u>	PAR-18-689	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.
<u>Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional)</u>	PAR-18-690	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.

<u>Innovative Therapies and Tools for Screenable Disorders (R21 Clinical Trial Optional)</u>	PAR-18-691	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.
<u>Content Development for the Newborn Screening Clearinghouse</u>		The Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB)	Ongoing	Develop and maintain a central clearinghouse of newborn screening information and provide expertise on newborn screening to inform this project.
<u>Child, Newborn, and Maternal Health Project</u>	RFA-391-13-000009	USAID-PAK	Ongoing	The purpose of this amendment is to cancel the Request for Application No.: 391-13-000009 for implementation of the ☒Child, Newborn, and Maternal Health Activity.☒

<u>Preliminary Guidance Related to Informed Consent for Research on Dried Blood Spots Obtained Through Newborn Screening</u>	NOT-OD-15-127	National Institutes of Health	Ongoing	The purpose of this Notice is to provide preliminary guidance to investigators engaged in newborn screening-related research regarding a new provision of the Newborn Screening Saves Lives Reauthorization Act of 2014 (P.L. 113-240).
--	---------------	-------------------------------	---------	---